The market was valued at USD 1.814 billion in 2024, about USD 1.978 billion in 2025, and is projected to reach roughly USD 4.691 billion by 2035, growing at a CAGR of approximately 9.02%. Growth is driven by regulatory incentives for biosimilars, advancements in biologics manufacturing, increasing patient and physician awareness, rising demand for affordable cancer treatments, and cos... https://www.marketresearchfuture.com/reports/biosimilar-bevacizumab-market-21960